vTv Therapeutics/VTVT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Ticker

VTVT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paul Sekhri

Employees

16

Headquarters

High point, United States

vTv Therapeutics Metrics

BasicAdvanced
$70M
Market cap
-
P/E ratio
-$8.76
EPS
0.59
Beta
-
Dividend rate
$70M
0.59161
$34.10
$7.38
12K
6.039
-63.15%
-2,570.57%
-128.59%
70.228
3.377
3.377
5,455.56%
-3.74%

vTv Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-480.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
∞%
Net income
-$4.8M
41.18%
Profit margin
-480.00%
-∞%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for vTv Therapeutics stock?

vTv Therapeutics (VTVT) has a market cap of $70M as of June 15, 2024.

What is the P/E ratio for vTv Therapeutics stock?

The price to earnings (P/E) ratio for vTv Therapeutics (VTVT) stock is 0 as of June 15, 2024.

Does vTv Therapeutics stock pay dividends?

No, vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next vTv Therapeutics dividend payment date?

vTv Therapeutics (VTVT) stock does not pay dividends to its shareholders.

What is the beta indicator for vTv Therapeutics?

vTv Therapeutics (VTVT) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell vTv Therapeutics stock

Buy or sell vTv Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing